NO20075368L - Antiinflammatoriske modaliteter - Google Patents

Antiinflammatoriske modaliteter

Info

Publication number
NO20075368L
NO20075368L NO20075368A NO20075368A NO20075368L NO 20075368 L NO20075368 L NO 20075368L NO 20075368 A NO20075368 A NO 20075368A NO 20075368 A NO20075368 A NO 20075368A NO 20075368 L NO20075368 L NO 20075368L
Authority
NO
Norway
Prior art keywords
inflammatory
inflammatory modalities
modalities
treatment
compounds
Prior art date
Application number
NO20075368A
Other languages
English (en)
Inventor
Alan James Husband
Catherine Walker
Michael John James
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901475A external-priority patent/AU2005901475A0/en
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Publication of NO20075368L publication Critical patent/NO20075368L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Antiinflammatoriske modaliteter er beskrevet med referanse til valgte isoflavonoidforbindelser, sammensetninger inneholdende samme og anvendelsen av nevnte forbindelser og/eller sammensetninger ved behandlingen, særlig for behandling av inflammatoriske sykdommer og relaterte tilstander.
NO20075368A 2005-03-24 2007-10-19 Antiinflammatoriske modaliteter NO20075368L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2005901475A AU2005901475A0 (en) 2005-03-24 Isflavonoid dimers
US66860905P 2005-04-06 2005-04-06
AU2005905985A AU2005905985A0 (en) 2005-10-28 Pain and anti-inflammatory modalities
PCT/AU2006/000407 WO2006108212A1 (en) 2005-03-24 2006-03-24 Anti-inflammatory modalities

Publications (1)

Publication Number Publication Date
NO20075368L true NO20075368L (no) 2007-12-11

Family

ID=37023310

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20075367A NO20075367L (no) 2005-03-24 2007-10-19 Isoflavonoide dimerer
NO20075368A NO20075368L (no) 2005-03-24 2007-10-19 Antiinflammatoriske modaliteter

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20075367A NO20075367L (no) 2005-03-24 2007-10-19 Isoflavonoide dimerer

Country Status (14)

Country Link
US (3) US20090131513A1 (no)
EP (3) EP1861402B1 (no)
JP (2) JP2008537545A (no)
CN (2) CN101184756B (no)
AT (1) ATE496921T1 (no)
AU (2) AU2006235194A1 (no)
CA (2) CA2602549A1 (no)
DE (1) DE602006019832D1 (no)
ES (1) ES2360130T3 (no)
IL (2) IL186217A0 (no)
MX (1) MX2007011493A (no)
NO (2) NO20075367L (no)
NZ (2) NZ561573A (no)
WO (2) WO2006099681A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010029995A1 (ja) * 2008-09-11 2012-02-02 協和発酵キリン株式会社 疼痛治療剤
JP6115303B2 (ja) * 2012-05-18 2017-04-19 Jnc株式会社 隣接基としてカルボニル基を有するフェノール化合物およびその用途
KR101539180B1 (ko) * 2014-09-18 2015-07-24 성균관대학교산학협력단 플라보노이드계 화합물을 포함하는 림프부종의 예방 또는 치료용 조성물
KR101533197B1 (ko) * 2014-09-18 2015-07-02 성균관대학교산학협력단 부테인을 포함하는 부종의 예방 또는 치료용 조성물
US10160740B2 (en) 2015-03-20 2018-12-25 The Board Of Trustees Of The Leland Stanford Junior University Carbonate-promoted carboxylation reactions for the synthesis of valuable organic compounds
EP3439642A4 (en) 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
RU2649119C1 (ru) * 2017-02-27 2018-03-29 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения язвенного колита
WO2019051548A1 (en) * 2017-09-15 2019-03-21 Norbio No. 2 Pty Ltd TREATMENT OF NEURO-INFLAMMATION
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
WO2021195698A1 (en) * 2020-03-30 2021-10-07 Noxopharm Limited Methods for the treatment of inflammation associated with infection
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN118373794B (zh) * 2024-04-17 2025-08-29 中国中医科学院中药研究所 一种异黄酮类化合物及其制备方法和在制药中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967362A (ja) 1995-09-01 1997-03-11 Sankyo Co Ltd ５α−還元酵素阻害剤ビスイソフラボン類
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
ES2244091T3 (es) * 1997-11-11 2005-12-01 Nikken Chemicals Company, Limited Derivado de n-hidroxiurea y composicion farmaceutica que lo contiene.
EE200100526A (et) * 1999-04-16 2002-12-16 Astrazeneca Ab Östrogeeni ß-retseptori ligandid
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AU2001259974A1 (en) * 2000-05-15 2001-11-26 Merck Frosst Canada & Co Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
WO2002074307A1 (en) * 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
CN1398586A (zh) * 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 新的取代庚酸衍生物治疗支气管哮喘和慢性阻塞性肺病
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
CA2542351A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Combinational radiotherapy and chemotherapy compositions and methods
EP1794141B1 (en) * 2004-09-21 2011-11-09 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy

Also Published As

Publication number Publication date
ATE496921T1 (de) 2011-02-15
JP2008533177A (ja) 2008-08-21
IL186217A0 (en) 2008-08-07
CN101203219B (zh) 2011-06-15
ES2360130T3 (es) 2011-06-01
AU2006235194A1 (en) 2006-10-19
EP1861402A1 (en) 2007-12-05
CA2602541A1 (en) 2006-09-28
CN101203219A (zh) 2008-06-18
EP2526941A1 (en) 2012-11-28
EP1861090A4 (en) 2010-01-06
HK1119557A1 (en) 2009-03-13
CN101184756B (zh) 2011-08-03
AU2006227555A1 (en) 2006-09-28
IL186218A0 (en) 2008-01-20
WO2006108212A1 (en) 2006-10-19
CN101184756A (zh) 2008-05-21
EP1861402A4 (en) 2009-12-30
US20090131513A1 (en) 2009-05-21
CA2602549A1 (en) 2006-10-19
MX2007011493A (es) 2008-04-14
DE602006019832D1 (de) 2011-03-10
EP1861090A1 (en) 2007-12-05
US20080306140A1 (en) 2008-12-11
US7700644B2 (en) 2010-04-20
NO20075367L (no) 2007-11-27
NZ561573A (en) 2010-05-28
JP2008537545A (ja) 2008-09-18
NZ561574A (en) 2010-03-26
US20120059176A1 (en) 2012-03-08
WO2006099681A1 (en) 2006-09-28
EP1861402B1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
NO20075368L (no) Antiinflammatoriske modaliteter
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
CR20130455A (es) Composiciones para el tratamiento de tumores
IL249838A0 (en) Telomerase activating compounds for use in treating diseases related thereto
NO20081636L (no) FAP - inhibitorer
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
LT2478907T (lt) Kompozicijos vėžiui gydyti
NO20071127L (no) Triazoloftalaziner
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DK1838716T3 (da) Olanzapinpamota-dihydrat
EP2216043A4 (en) USE OF GSE24.2 INDUCTOR AGENTS FOR DEVELOPING PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CELL SENESCENCE
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi
DK1951274T3 (da) Parapoxvirusser i kombination med klasssiske cytotoksiske kemoterapeutiske midler som biokemoterapi til behandling af cancer
ATE458738T1 (de) 2-alkoxy-3,4,5-trihydroxy-alkylamid- benzothiazepine, ihre herstellung und verwendung sowie diese enthaltende zusammensetzungen
ITMI20050891A1 (it) Formulazioni per il trattamento di psoriasi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application